Monitor the strategic alternatives review for potential M&A outcomes. The revenue miss and narrowed guidance suggest near-term headwinds, but the EPS beat and strong cash flow support the current valuation. Watch for any update on the strategic review in the coming weeks.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $10.95entry
- T+1 · 13d ago +4.34%α +2.69% · $11.42
- T+5 · 7d ago +2.15%α +2.73% · $11.18
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Bioventus reported Q3 2026 non-GAAP EPS of $0.17, beating the $0.16 consensus by 6.3%, while revenue of $142.4M missed the $149.5M consensus by 4.7%. The company reaffirmed its full-year adjusted EPS guidance of $0.75-$0.79 but narrowed net sales guidance to $590M-$595M, implying 4-5% growth. The ongoing review of strategic alternatives adds an M&A overhang.
Key Financial Metrics
Key Facts
- Non-GAAP EPS of $0.17 beat consensus of $0.16 by 6.3%
- Revenue of $142.4M missed consensus of $149.5M by 4.7%
- Revenue grew 2.7% YoY, below the 5% bullish threshold
- Pain Treatments revenue grew 6.2% YoY to $71.3M
- Restorative Therapies revenue declined 3.4% YoY to $20.6M
- Adjusted EBITDA of $28.4M grew 7% YoY
- Operating cash flow was $20.7M in Q3
- Company made a $15M discretionary principal prepayment on term loan
- Full-year adjusted EPS guidance reaffirmed at $0.75-$0.79
- Full-year net sales guidance updated to $590M-$595M (4-5% growth)
- Company continues to review potential strategic alternatives
Financial Impact
Non-GAAP EPS beat by $0.01 (6.3%), revenue miss of $7.1M (4.7%)
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Pain Treatments | $71.3M | +6.2% |
| Surgical Solutions | $50.5M | +0.7% |
| Restorative Therapies | $20.6M | -3.4% |
Risk Factors
- Revenue miss of 4.7% vs consensus signals softer top-line momentum
- Restorative Therapies segment declining 3.4% YoY
- Strategic alternatives review creates uncertainty around future direction
- Cash and cash equivalents declined to $30.7M from $51.2M at year-end 2025
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3393722 |
Track record
18 reports on BVS
2 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +37.19% at T+60 after the May 8, 2026 report. 3 of 7 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $10.66 Now $10.46 −1.88% settles Feb 11
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $10.61 Now $10.46 −1.41% settles Feb 4
- Nov 2, 202614d ago 8-K Neutral 5/10 No price data
- Nov 2, 202614d ago Press Release Neutral 5/10 Viewing Entry $10.95 Now $10.46 −4.43% settles Feb 1
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $14.65 Now $10.46 −28.60% settles Jan 26
- Aug 15, 202613w ago Institutional Cluster Mixed 5/10 Entry $13.88 to $11.02 Now $10.46 −24.64% ▼ −20.64% −17.88% vs SPY
- Aug 5, 202614w ago 8-K Bullish 7/10 No price data
- Aug 5, 202614w ago Press Release Bullish 7/10 Entry $15.26 to $14.86 Now $10.46 −31.45% ▼ −2.62% −2.81% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bearish 4/10 Entry $8.68 to $14.07 Now $10.46 −20.51% ▼ −62.10% −57.70% vs SPY
- Jun 2, 202623w ago Press Release Bearish 6/10 Entry $8.11 to $13.97 Now $10.46 −28.98% ▼ −72.26% −71.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers